We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+0.2%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.9B
AUM Growth
-$1.94B
Cap. Flow
-$1.04B
Cap. Flow %
-4.99%
Top 10 Hldgs %
40.27%
Holding
168
New
18
Increased
43
Reduced
28
Closed
22

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$381M
2
MSFT icon
Microsoft
MSFT
+$266M
3
CRM icon
Salesforce
CRM
+$235M
4
K
Kellanova
K
+$186M
5
ARMK icon
Aramark
ARMK
+$178M

Top Sells

Rank Stock Value
1
ABNB icon
Airbnb
ABNB
+$319M
2
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$221M
3
AON icon
Aon
AON
+$181M
4
BMY icon
Bristol-Myers Squibb
BMY
+$180M
5
HES
Hess
HES
+$150M

Sector Composition

Rank Sector Weight
1 Healthcare 37.95%
2 Technology 14.96%
3 Financials 12.32%
4 Communication Services 7.9%
5 Industrials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
126
Pacific Biosciences
PACB
$420M
$159K ﹤0.01%
135,000
– –
QURE icon
127
uniQure
QURE
$3.36B
$148K ﹤0.01%
+14,000
New +$196K
OSCR icon
128
Oscar Health
OSCR
$9.89B
$144K ﹤0.01%
11,000
– –
ALT icon
129
Altimmune
ALT
$605M
$138K ﹤0.01%
27,600
– –
EVH icon
130
Evolent Health
EVH
$536M
$133K ﹤0.01%
14,000
– –
FOLD
131
DELISTED
Amicus Therapeutics
FOLD
$131K ﹤0.01%
16,000
– –
SNDX icon
132
Syndax Pharmaceuticals
SNDX
$1.75B
$123K ﹤0.01%
10,000
– –
ARDX icon
133
Ardelyx
ARDX
$1B
$113K ﹤0.01%
23,000
– –
DYN icon
134
Dyne Therapeutics
DYN
$4.87B
$105K ﹤0.01%
10,000
-219,121
-96% -$3.13M
NVAX icon
135
Novavax
NVAX
$1.47B
$103K ﹤0.01%
16,000
– –
COGT icon
136
Cogent Biosciences
COGT
$6.37B
$102K ﹤0.01%
17,000
– –
IOVA icon
137
Iovance Biotherapeutics
IOVA
$3.76B
$86.6K ﹤0.01%
26,000
– –
SLDPW icon
138
Solid Power Inc Warrant
SLDPW
$6.93M
$68.9K ﹤0.01%
405,316
– –
GERN icon
139
Geron
GERN
$977M
$68.4K ﹤0.01%
43,000
– –
BYSI icon
140
BeyondSpring
BYSI
$29.6M
$58K ﹤0.01%
+19,000
New +$32K
CCCC icon
141
C4 Therapeutics
CCCC
$492M
$44.8K ﹤0.01%
28,000
– –
ANNA
142
AleAnna Inc
ANNA
$116M
$35K ﹤0.01%
78,400
– –
CGC
143
Canopy Growth
CGC
$472M
$27.3K ﹤0.01%
30,000
– –
IRWD icon
144
Ironwood Pharmaceuticals
IRWD
$709M
$19.1K ﹤0.01%
13,000
– –
NVNIW
145
Nvni Group Limited Warrants
NVNIW
$10.7K ﹤0.01%
375,000
– –
RVMDW icon
146
Revolution Medicines Inc Warrant
RVMDW
$130M
$4.56K ﹤0.01%
120,085
– –
ABNB icon
147
Airbnb
ABNB
$110B
– –
-2,429,200
Closed -$319M
ASHR icon
148
CALL
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
$1.57B
– –
-1,020,000
Closed -$27M
BMY icon
149
Bristol-Myers Squibb
BMY
$137B
– –
-3,188,000
Closed -$180M
ELEV
150
DELISTED
Elevation Oncology
ELEV
– –
-3,527,482
Closed -$1.98M
3 4 5
6
7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2025 Portfolio in Review

As of Q1 2025, Thomas Steyer held 168 positions worth $20.9B, down 8.5% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer withdrew a net $1.04B in Q1 2025, closing 22 positions and reducing 28 holdings. Its most notable exit was Airbnb, an estimated $319M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 34% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Intra-Cellular Therapies Inc. worth $403M.

  • Thomas Steyer's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 3,055,000 shares worth $403M.
  • Thomas Steyer added most to Microsoft in Q1 2025, an estimated $266M increase.
  • Thomas Steyer's biggest Q1 2025 reduction was Aon, cutting an estimated $181M.
  • Thomas Steyer fully exited Airbnb in Q1 2025, selling an estimated $319M.
  • Thomas Steyer's ten largest holdings make up 40% of its $20.9B portfolio in Q1 2025.
  • Thomas Steyer opened 18 new positions and closed 22 in Q1 2025.
  • Thomas Steyer's portfolio value fell 8.5% quarter-over-quarter to $20.9B.

Based on Farallon Capital Management's 13F filing for Q1 2025, filed 15 May 2025.